活血化瘀中药制剂治疗肝硬化门脉高压脾切除术后门静脉血栓形成的研究进展

Ding-qi ZHANG; Yong-ping MU; Ying XU; Jia-mei CHEN; Ping LIU; Wei LIU

doi:10.1007/s11655-020-3271-8

Your Location：

Home >

Browse articles >

活血化瘀中药制剂治疗肝硬化门脉高压脾切除术后门静脉血栓形成的研究进展

Review | Updated：2022-09-08

- 活血化瘀中药制剂治疗肝硬化门脉高压脾切除术后门静脉血栓形成的研究进展
- Research Progress in Chinese Medicine Preparations for Promoting Blood Circulation and Removing Blood Stasis for Cirrhotic Patients with Portal Vein Thrombosis Following Splenectomy
- Chinese Journal of Integrative Medicine 2022年28卷第9期页码：855-863
- Affiliations：
  
  1.Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai (201203), China
  2.Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai (201203),China
  3.Institute of Interdisciplinary Complex Research, Shanghai University of Traditional Chinese Medicine, Shanghai(201203), China
- Author bio：
  
  Associate Prof. LIU Wei, E-mail:lwhzayl@163.com
- Funds：
  
  the National Natural Science Foundation of China(81703681;81530101);the Shanghai Sailing Program(17YF1419800)
- DOI：10.1007/s11655-020-3271-8
  中图分类号：
- 纸质出版日期：2022-09，
  
  网络出版日期：2020-07-20，
  
  录用日期：2020-02-15
Scan for full text
Ding-qi ZHANG, Yong-ping MU, Ying XU, 等. 活血化瘀中药制剂治疗肝硬化门脉高压脾切除术后门静脉血栓形成的研究进展[J]. Chinese Journal of Integrative Medicine, 2022,28(9):855-863.

Ding-qi ZHANG, Yong-ping MU, Ying XU, et al. Research Progress in Chinese Medicine Preparations for Promoting Blood Circulation and Removing Blood Stasis for Cirrhotic Patients with Portal Vein Thrombosis Following Splenectomy[J]. Chinese Journal of Integrative Medicine, 2022,28(9):855-863.
Ding-qi ZHANG, Yong-ping MU, Ying XU, 等. 活血化瘀中药制剂治疗肝硬化门脉高压脾切除术后门静脉血栓形成的研究进展[J]. Chinese Journal of Integrative Medicine, 2022,28(9):855-863. DOI： 10.1007/s11655-020-3271-8.

Ding-qi ZHANG, Yong-ping MU, Ying XU, et al. Research Progress in Chinese Medicine Preparations for Promoting Blood Circulation and Removing Blood Stasis for Cirrhotic Patients with Portal Vein Thrombosis Following Splenectomy[J]. Chinese Journal of Integrative Medicine, 2022,28(9):855-863. DOI： 10.1007/s11655-020-3271-8.

摘要

本文综述了活血化瘀中药制剂治疗肝硬化门脉高压 (cirrhotic portal hypertension

CPH) 脾切除术后门静脉血栓形成 (portal vein thrombosis

PVT) 的疗效. 根据已发表的中药制剂对CPH脾切除术后PVT的临床研究

评估干预治疗后PVT发生率的变化

并探讨中药制剂潜在的活性成分及作用机制. 目前研究表明

注射用红花黄色素、丹参注射液、丹红注射液及复方丹参滴丸等单用或联合抗凝治疗均取得较好疗效. 此外

复方鳖甲软肝片和安洛化纤丸也能显著改善肝硬化患者门静脉系统血流动力学紊乱. 基于中药制剂对CPH患者脾切除术后PVT的改善作用

中药制剂单用或联合抗凝剂治疗肝硬化PVT应当在今后的研究中给予更多关注.

Abstract

This article presented an overview of the therapeutic effects of Chinese medicine (CM) preparations for promoting blood circulation and removing blood stasis for patients with portal vein thrombosis (PVT) after splenectomy. Based on published clinical researches of CM preparations for PVT after splenectomy in patients with cirrhotic portal hypertension (CPH)

this paper evaluated the incidence of PVT

and explored potential active components and mechanisms of CM preparations. Safflower Yellow Injection

Danshen Injection

Danhong Injection

and Compound Danshen Dropping Pill achieved good curative effect alone or combined with anticoagulant therapy. In addition

Compound Biejia Ruangan Tablet and Anluo Huaxian Pill can also significantly improve the hemodynamic disorders of portal vein system in patients with cirrhosis. Considering the role of CM preparations in ameliorating the incidence of PVT after splenectomy in patients with CPH

we suggested that future research should provide more attention to CM alone or CM combined with anticoagulant for cirrhosis with PVT.

关键词

门静脉血栓脾切除肝硬化门静脉高压症中药制剂活血化瘀

Keywords

portal vein thrombosissplenectomycirrhotic portal hypertensionChinese medicine preparationspromoting blood circulation and removing blood stasis

references

Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010;31:366-374.

DeLeve LD, Valla DC, Guadalupe GT. Vascular disorders of the liver. Hepatology 2009;49:1729-1764.

Cheng LF, Jia JD, Xu XY, et al. Esophagogastric variceal bleeding in cirrhotic portal hypertension: consensus on prevention and management (2008). Chin Med J 2009;122:766-775.

Qi XS, Han GH, Ye C, et al. Splenectomy causes 10-fold increased risk of portal venous system thrombosis in liver cirrhosis patients. Med Sci Monit 2016;22:2528-2550.

Danno K, Ikeda M, Sekimoto M, et al. Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy. Surgery 2009;145:457-466.

Rottenstreich A, Kleinstern G, Spectre G, et al. Thromboembolic events following splenectomy: risk factors prevention, management and outcomes. World J Surg 2018;42:42675-681.

DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009;49:1729-1764.

Leona VK, Andrea DG, Jonel T, et al. Portal vein thrombosis in patients with cirrhosis. Gastroenterol Rep(Oxf) 2017;5:148-156.

Guo WS, Li RX, Li TC. Effect of Erigerontis Injection on prevention of portal vein thrombosis after portal azygos disconnection. Guangdong Med J (Chin) 2012;33:3208.

Yao HN, Fu YQ. Clinical study on the prevention and treatment of portal vein thrombosis after portal hypertension disconnection with integrated traditional Chinese and Western medicine.Yunnan J Tradit Chin Med Mater Med (Chin) 2008;29:7-8.

Gîrleanu I, Trifan A, Stanciu C, et al. Portal vein thrombosis in cirrhotic patients-it is always the small pieces that make the big picture. World J Gastroenterol 2018;24:4419-4427.

He S, He F. Predictive model of portal venous system thrombosis in cirrhotic portal hypertensive patients after splenectomy. Int J Clin Exp Med 2015;8:4236-4242.

Jiang GQ, Bai DS, Chen P, et al. Risk factors for portal vein system thrombosis after laparoscopic splenectomy in cirrhotic patients with hypersplenism. J Laparoendosc Adv Surg Tech A 2016;26:419-423.

Senzolo M, Rodriguez K, Nadal E, et al. Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension. Br J Surg 2010;97:910-916.

Huang L, Yu Q, Wang J. Association between changes in splanchnic hemodynamics and risk factors of portal venous system thrombosis after splenectomy with periesophagogastric devascularization. Med Sci Monit 2018;24:4355-4362.

Zhang H, Li B. Analysis on pathological changes of portal vein and hepatic artery in patient with cirrhotic portal hypertension. Chongqing Med J (Chin) 2017;46:2767-2773.

Basili S, Pastori D, Raparelli V, et al. Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. Therap Adv Gastroenterol 2018;11:1-10.

Mantaka A, Augoustaki A, Kouroumalis EA, et al. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol 2018;31:315-329.

Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143;1253-1260.

Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691-697.

Senzolo M, Sartori T, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012;32:919-927.

Werner KT, Sando S, Carey EJ, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci 2013;58:1776-1780.

Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010;44:448-451.

Chen H, Liu L, Qi X, et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2016;28:82-89.

Dell'Era A, Iannuzzi F, Fabris FM, et al. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Dig Liver Dis 2014;46:152-156.

Jiang GQ, Xia BL, Chen P, et al. Anticoagulation therapy with warfarin versus low-dose aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection.J Laparoendosc Adv Surg Tech A 2016;26:517-523.

Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147-156.

Zhou JB, Luo BY, Liu CW, et al. Effects of early antiplatelet therapy after splenectomy with gastro-oesophageal devascularization. ANZ J Surg 2018;88:725-729.

Ma XJ, Yin HJ, Chen KJ. Differential gene expression profiles in coronary heart disease patients of blood stasis syndrome in traditional Chinese medicine and clinical role of target gene. Chin J Integr Med 2009;15:101-106.

Xu LM, Liu P, Shen XZ, et al. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019). J Clin Hepat (Chin) 2019;35:1444-1449.

Duan L, Pan ZX. Application of Safflower Yellow in prevention of portal vein thrombosis after splenectomy.Chin Med Modern Dis Educ China (Chin) 2015;8:78.

Kang X, Zhang Q. Early application of low molecular weight heparin and Danshen Injection in prevention of portal vein thrombosis after splenectomy and devascularization in liver cirrhosis. Proceed Clin Med (Chin) 2010;19:16, 33.

Yao XF. Observation on the effect of Xueshuantong Injection in prevention of portal vein thrombosis after devascularization.Pract Clin J Integr Tradit Chin West Med (Chin) 2012;12:30-31.

Huang HF, Meng BH. Shuxuening Injection prevents portal vein thrombosis after devascularization in portal hypertension. Heilongjiang Med Pharma (Chin) 2006;29:75.

Wan JH, Yang L, Dai XP. Application of compound Danshen Dropping Pills combined with aspirin enteric-coated tablets in postoperative portal hypertension. Jiangxi Med J (Chin) 2015;50:775-777.

Jiao SL, Zhao XR, Du SQ, et al. Intervention of large-dose compound Danshen Injection combined with low-dose low-molecular-weight heparin calcium on portal vein thrombosis after splenectomy for liver cirrhosis. Chin Hepatol (Chin)2018;23:623-625.

Yuan T, Chen Y, Zhou X, et al. Effectiveness and safety of Danshen Injection on heart failure: protocol for a systematic review and meta-analysis. Medicine (Baltimore)2019;98:e15636.

Zou JB, Zhang XF, Wang J, et al. The therapeutic efficacy of Danhong Injection combined with percutaneous coronary intervention in acute coronary syndrome: a systematic review and meta-analysis. Front Pharmacol 2018;9:550.

Liao P, Wang L, Guo L, et al. Danhong Injection (a traditional Chinese patent medicine) for acute myocardial infarction: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2015;2015:646530.

Tan D, Wu JR, Liu S, et al. Meta-analysis of efficacy of Shuxuening Injection in the treatment of cerebral infarction.J Pharmacoepidemiol 2016;8:492-498.

Wang X, Wu JR, Zhang D, et al. Meta-analysis of efficacy of Xueshuantong Injection in the treatment of acute cerebral infarction. J Pharmacoepidemiol 2016;10:616-622.

Liu S, Wu JR, Zhang D, et al. Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials. BMC Complement Altern Med 2018;18:120.

Li HQ, Wei JJ, Xia W, et al. Promoting blood circulation for removing blood stasis therapy for acute intracerebral hemorrhage: a systematic review and meta-analysis. Acta Pharmacol Sin 2015;36:659-675.

Liu YH, Lin DX, Shi SZ, et al. The influence of Compound Biejia Ruangan Tablets combined with entecavir therapy on serum D-dimer in patients with compensated liver cirrhosis.Chin J Integr Tradit West Med Liver Dis (Chin) 2016;26:84-85.

Shi SZ, Chen XR, Gu YR, et al. Effect of Anluohuaxian Pill combined with entecavir on portal vein hemodynamics of patients with hepatitis B cirrhosis. Chin J Integr Tradit West Med Liver Dis (Chin) 2016;26:336-337.

Yang YP, Li RH, Yu P. Effects of Anluohuaxian Pill combined with entecavir on portal hemodynamics in patients with hepatitis B liver cirrhosis. Med J Chin People's Health (Chin) 2017;29:61-62.

Li W, Liu J, He P, et al. Hydroxysafflor Yellow A protects methylglyoxal-induced injury in the cultured human brain microvascular endothelial cells. Neurosci Lett 2013;549:146-150.

Liu L, Duan JA, Tang Y, et al. Taoren-Honghua herb pair and its main components promoting blood circulation through influencing on hemorheology, plasma coagulation and platelet aggregation. J Ethnopharmacol 2012;139:381-387.

Li ZY, Tu XH. Pharmacological research progress of safflower yellow. Tradit Chin Drug Res Clin Pharmacol(Chin) 2005;16:153-156.

Ji XY, Tan BK, Zhu YZ. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 2000;21:1089-1094.

Xing XW, Jin XY, Yan YP, et al. Protective effects of tanshinone ⅡA on endothelial progenitor cells injured by tumor necrosis factor-α. Mol Med Rep 2015;12:4055-4062.

Cao HM, Wu J, Jia LQ, et al. Progress in study of tanshinone ⅡA's pharmacological effects on cardiovascular system. World Chin Med (Chin) 2017;12:1718-1722.

Yu C, Qi D, Lian W, et al. Effects of Danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in rats. PLoS One 2014;9:e110124.

Xu C, Wang W, Wang B, et al. Analytical methods and biological activities of Panax notoginseng saponins: recent trends. J Ethnopharmacol 2019;23:443-465.

Yang J, Yuan YZ, Wei GF, et al. Advances on chemical constituents and pharmacological activities of Panax notoginseng. World Sci Tech Mod Tradit Chin Med Mater Med (Chin) 2017;19:1641-1647.

Wang R, Wang M, Zhou J, et al. Shuxuening Injection protects against myocardial ischemia-reperfusion injury through reducing oxidative stress, inflammation and thrombosis. Ann Trans Med 2019;7:562.

Zhang PF, Liao LJ, Deng Z. Research progress of pharmacological effects and clinical application of Ginkgo Biloba extract. Liaoning J Tradit Chin Med (Chin) 2017;44:426-429.

Geng T, Shen WW, Wang JJ, et al. Research development of Ginkgo Terpene Lactones. China J Chin Mater Med(Chin) 2018;43:1384-1391.

Fan YD, Han JQ. Pharmacological action and clinical application of breviscapine. Hainan Med J (Chin) 2017;28:627-629.

Huang JG, Xie M, Zhang X, et al. Hypoxemia induced the changing structure of the lung tissue in SD rat though changing blood clotting and the effects of breviscapine's intervention. J Sichuan Univ (Med Sci Edit, Chin) 2014;45:567-571.

Li TJ, Zheng JM, Rui YC, et al. Protective effects of caffeoyl conjugation compounds from erigeron breviscapus on the injury of bovine cerebral microvascular endothelial cells induced by lysophosphatidylcholine. Acad J Second Milit Med Univ (Chin) 2001; 22:255-257.

Feng X, Li Y, Wang Y, et al, Danhong Injection in cardiovascular and cerebrovascular diseases: pharmacological actions, molecular mechanisms, and therapeutic potential. Pharmacol Res 2019;1:139.

Chang LY, Zhu Y, Gao XM. Research progress of antithrombotic effect of Danhong Injection. J Tianjin Univ Tradit Chin Med (Chin) 2013;32:246-249.

Li PL, Liu H, Liao YQ, et al. Interactions between Danhong Injection components and anti-thrombotic targets based on network pharmacology. J Sun Yat-sen Univ (Nat Sci Edit, Chin) 2018;57:121-127.

Li Q. Research progress and clinical application of compound Danshen Dripping Pills. China J Tradit Chin Med Pharm (Chin) 2018;33:2989-2991.

Kuang QL. Clinical observation of Xiangdan Injection in the treatment of coronary heart disease angina pectoris. J Emerg Tradit Chin Med (Chin) 2006;5:454-455.

Shen P, Lin YH, Guo WP, et al. Efficacy of low molecular weight heparin and Xiangdan Injection for prophylaxis against venous thromboembolism in the patients undergoing laparoscopic gynecological malignant tumor surgery. Prac J Med Pharm (Chin) 2015;32:607-609.

Li YW, Liu ZQ, Zhao Y, et al. Network analysis of main active ingredients-target-pathway of Xiangdan Injection in treatment of coronary heart disease. Chin Pharm J (Chin)2018;53:1927-1935.

Song Y, Zhao J, Wang S, et al. The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies. Medicine(Baltimore) 2019;98:e15732.

Guo RB, Wang GF, Zhao AP, et al. Paeoni-florin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-κB-mediated inflammatory responses. PLoS One 2012:7:e49701.

Ye SS, Mao BY, Yang L, et al. Thrombosis recanalization by paeoniflorin through the upregulation of urokinase-type plasminogen activator via the MAPK signaling pathway. Mol Med Rep 2016;13:4593-4598.

Zhang N, Yao Y, Xue W, et al. Early prophylactic anticoagulation for portal vein system thrombosis after splenectomy: a systematic review and meta-analysis.Biomed Rep 2016;5:483-490.

Turpie AG. Pharmacology of the low-molecular-weight heparins. Am Heart J 1998;135:s329-s335.

Bollati M, Gaita F, Anselmino M. Antiplatelet combinations for prevention of atherothrombotic events. Vasc Health Risk Manag 2011;7:23-30.

Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 2011;130:46-58.

Zhu QX, Li XD. Clinical effect of adefovir dipivoxil combined with compound Bijia Ruangan Tablets in treatment of patients with chronic hepatitis B. J Prac Hepatol 2015;18:258-261.

Zhao JJ, Chen XQ, Tuohu TX. The anti-hepatic fibrosis effect of Anluohuaxian Pill combined with lamivudine on the treatment of chronic hepatitis B patients. J Clin Hepatol 2010;26:413-414.

Shi D, Peng YG. Progress of study in antithrombotic drugs in traditional Chinese medicine. J Hunan Univ Med (Chin)2011;31:75-78.

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

暂无数据